| 2.6601 -0.02 (-0.74%) | 08-26 15:09 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.46 | 1-year : | 4.05 |
| Resists | First : | 2.97 | Second : | 3.46 |
| Pivot price | 2.54  |
|||
| Supports | First : | 2.4 | Second : | 2.04 |
| MAs | MA(5) : | 2.62 |
MA(20) : | 2.46 |
| MA(100) : | 3.68  |
MA(250) : | 7.42 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.1 |
D(3) : | 57.4 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 19.35 | Low : | 1.7 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ATOS ] has closed below upper band by 26.6%. Bollinger Bands are 60.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.69 - 2.7 | 2.7 - 2.71 |
| Low: | 2.55 - 2.56 | 2.56 - 2.58 |
| Close: | 2.66 - 2.68 | 2.68 - 2.7 |
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Tue, 18 Aug 2026
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate - simplywall.st
Mon, 10 Aug 2026
Weekly Recap: Q2 net loss, financing and (Z)-endoxifen Phase 2 progress - TradingView
Fri, 07 Aug 2026
Atossa's Phase 2 Breast Cancer Trial Completes Enrollment - Stock Titan
Tue, 28 Jul 2026
Five New Compounds Show Activity in Breast Cancer Models With ESR1 Mutations - Stock Titan
Thu, 25 Jun 2026
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Are Analysts Optimistic? - simplywall.st
Thu, 11 Jun 2026
Atossa Therapeutics Prices Registered Direct Offering at $3.30, Netting About $4.1 Million - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 17.3 (%) |
| Shares Short | 760 (K) |
| Shares Short P.Month | 704 (K) |
| EPS | -4.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50.7 % |
| Return on Equity (ttm) | -89.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.62 |
| PEG Ratio | 0 |
| Price to Book value | 0.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|